Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Elevated lipoprotein(a) (Lp[a]) is a significant risk factor for cardiovascular diseases, including coronary heart disease, stroke, and heart failure.
• Lp[a]) comprises low-density lipoprotein-like particles with apolipoprotein A (apo[a]) and apolipoprotein B-100, contributing to pro-thrombotic, pro-inflammatory, and pro-atherogenic effects.
• Serum Lp[a] levels are genetically determined by apo(a) isoforms, with shorter isoforms linked to higher particle synthesis rates.

Purpose of the Study:

• To provide a comprehensive review of RNA-based therapeutic approaches for reducing lipoprotein(a) levels.
• To discuss recent advances and challenges in developing RNA therapeutics for cardiovascular disease risk reduction.

Main Methods:

• Review of genetic and epidemiologic studies on Lp(a) and cardiovascular disease.
• Analysis of current clinical trial data for RNA-based drugs targeting apo(a) expression.
• Detailed overview of RNA therapeutics designed to lower Lp(a).

Main Results:

• No approved pharmacological therapies currently exist to effectively reduce Lp(a) levels.
• Several RNA-based drugs (pelacarsen, olpasiran, SLN360, lepodisiran) are in clinical trials targeting apo(a) expression.
• These RNA therapeutics represent promising strategies for cardiovascular risk reduction.

Conclusions:

• Lowering Lp(a) levels is a key strategy for mitigating cardiovascular disease risk.
• RNA-based therapeutics offer a novel and promising approach to reduce Lp(a) and its associated cardiovascular risks.
• Ongoing clinical trials are crucial for evaluating the efficacy and safety of these emerging treatments.